Key HighlightsaTyr Pharma secured FDA alignment on its Phase 3 trial protocol for efzofitimod targeting pulmonary sarcoidosis patients.Study activities are scheduled to commence in Q4 2026.Shares of ATYR jumped 5% following the regulatory update.The clinical trial will recruit approximately 372 participants over a 54-week period.Trial parameters are supported by positive subgroup findings from the preceding EFZO-FIT Phase 3 study.aTyr Pharma (ATYR) shares advanced 5% during Wednesday’s trading session after the biotech firm disclosed successful protocol alignment with the U.S. Food and Drug Administration for its planned Phase 3 clinical trial. The study will evaluate efzofitimod’s effectiveness in treating chronic pulmonary sarcoidosis patients.aTyr Pharma, Inc., ATYRThe San Diego headquartered biotechnology company revealed plans to initiate trial-related operations during the fourth quarter of 2026. Concurrent regulatory submission efforts will proceed in both United States and European markets as the study advances.Pulmonary sarcoidosis represents a type of interstitial lung disease where affected individuals frequently encounter scarce therapeutic alternatives, particularly those requiring sustained medical intervention.Trial Design and StructureThe upcoming Phase 3 investigation will employ a global, randomized, double-blind, placebo-controlled methodology. Scientists structured the study to assess both therapeutic effectiveness and safety profiles of efzofitimod among patients experiencing moderate to severe disease manifestations.Spanning 54 weeks, the clinical trial will divide participants into two equal cohorts. One group will receive 5.0 mg/kg efzofitimod while the control group gets placebo treatment, both administered intravenously every three weeks for 17 total doses.aTyr plans to recruit approximately 372 study participants. Qualified candidates must maintain stable, low-dose oral corticosteroid therapy or background immunosuppressant treatment, which will remain constant throughout the study duration.Researchers established forced vital capacity change from baseline measurement at week 48 as the primary endpoint. An important secondary endpoint will monitor shifts in King’s Sarcoidosis Questionnaire-Lung scores during the identical timeframe.Foundation in Previous Clinical EvidenceThe current trial framework stems from rigorous analysis. It draws upon subgroup data extracted from the preceding EFZO-FIT Phase 3 investigation.That subgroup examination concentrated on individuals with restrictive lung disease, characterized by forced vital capacity at 80% or below of predicted values with normal FEV1/FVC ratios. These participants demonstrated notable lung function improvements when administered the 5.0 mg/kg dosage versus placebo treatment.Additional benefits emerged across various patient-reported outcome measures, including KSQ-Lung assessments. aTyr unveiled these results during the World Association of Sarcoidosis and Other Granulomatous Disorders 2026 Congress.Chief Executive Officer Sanjay Shukla indicated the company obtained FDA feedback early in the week and characterized the regulatory alignment as a significant developmental milestone. He emphasized the scarcity of therapeutic options for chronic sarcoidosis sufferers as evidence of the drug’s potential impact within this treatment landscape.Efzofitimod functions as a biologic immunomodulator. Its mechanism involves targeting activated myeloid cells via neuropilin-2, seeking to address inflammation without causing broad-spectrum immune system suppression.The therapeutic candidate is simultaneously undergoing evaluation in a separate Phase 2 investigation for systemic sclerosis-related interstitial lung disease. That study, designated EFZO-CONNECT, operates in parallel with the sarcoidosis development program.aTyr acknowledged that advancing the Phase 3 sarcoidosis trial necessitates securing additional financial resources. The company indicated potential funding avenues including equity or debt financing instruments, grant opportunities, strategic partnerships or licensing arrangements.The announcement contained no specific funding schedule or monetary requirements.The post aTyr Pharma (ATYR) Gains 5% After Securing FDA Protocol Approval for Phase 3 Sarcoidosis Study appeared first on Blockonomi.